title: Ibrutinib: better combined with other drugs?
authors.affiliation: Division of Molecular Oncology and Department of Onco-Hematology, IRCCS Ospedale San Raffaele, Milan 20132, Italy; Università Vita-Salute San Raffaele, Milan 20132, Italy. Electronic address: ghia.paolo@hsr.it.
authors.forename: Paolo
authors.initials: P
authors.lastname: Ghia
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010880:Piperidines; D011720:Pyrazoles / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000069283:Rituximab; D000225:Adenine